Revolution Medicines Is A Clinical Stage Precision Oncology Company Based In Redwood Citycaliforniathe Company Specializes In Developing Targeted Therapies For Cancers Driven By Mutations In The Ras Family Of Genessince Pivoting To Oncology In 2018Revolution Medicines Has Focused On The Ras Pathwaywhich Is A Key Factor In Many Aggressive Cancersthe Company Has Successfully Raised Significant Funding To Support Its Ras Focused Pipeline The Company S Pipeline Includes Several Promising Candidatessuch As Rmc 6236An Oral Multi Selective Inhibitor Targeting Pancreatic Ductal Adenocarcinoma And Non Small Cell Lung Cancerand Rmc 6291A Covalent Inhibitor Aimed At Specific Mutations In These Cancersadditionallyrevolution Medicines Is Advancing Several Preclinical Candidates That Target Ras Onmutant Selective Pathwaysthe Company Has Also Formed Strategic Collaborationsincluding A Notable Development Deal With Sanofi To Enhance Its Ras Targeted Therapies
